PT-141 (Bremelanotide) is the only prescription peptide that works centrally through the brain to restore genuine desire and arousal — for both men and women. No cardiovascular effects. No waiting for stimulation. Just natural desire, restored. Prescribed online by licensed U.S. providers. Starting at $178.
Get PT-141 Prescribed →PT-141, also known as Bremelanotide, is a synthetic peptide that acts as a melanocortin receptor agonist — specifically activating MC3R (Melanocortin 3 Receptor) and MC4R (Melanocortin 4 Receptor) in the hypothalamus. Unlike conventional sexual dysfunction treatments such as Viagra or Cialis, which work peripherally by increasing blood flow to the genitals, PT-141 works centrally through the central nervous system to promote genuine arousal and sexual desire at the neurological level.
This central mechanism is what makes PT-141 uniquely powerful — and uniquely different. It doesn't just facilitate a physical response; it activates the brain's desire pathways, promoting natural arousal that comes from within rather than from cardiovascular manipulation. This also means PT-141 does not carry the cardiovascular risks (blood pressure changes, contraindications with nitrates) associated with PDE5 inhibitors. It can even be combined with ED medications for enhanced effect.
Critically, PT-141 is effective for both men and women. In men, it addresses erectile dysfunction, low libido, and difficulty achieving arousal. In women, it is used for Female Sexual Arousal Disorder (FSAD) and Hypoactive Sexual Desire Disorder (HSDD) — conditions that PDE5 inhibitors cannot treat. Available as an injection (2mg/dose) or nasal spray, PT-141 offers flexible dosing with effects lasting 6–12 hours. View full sexual health catalog →
Activates MC3R and MC4R receptors in the hypothalamus — the brain's desire center — to promote genuine arousal from within the nervous system, not just peripheral blood flow.
Stimulates dopaminergic pathways associated with reward and pleasure, restoring the neurochemical environment that supports desire, motivation, and sexual engagement.
Both sexes have MC3R/MC4R receptors in the hypothalamus. PT-141 activates desire pathways in men (ED, low libido) and women (FSAD, HSDD) through identical mechanisms.
Unlike PDE5 inhibitors (Viagra, Cialis), PT-141 doesn't manipulate blood pressure or interact with nitrates. Safe for patients who cannot use cardiovascular-acting sexual medications.
Understanding how PT-141 differs from conventional treatments helps you choose the right approach for your needs.
| Feature | PT-141 | Viagra/Cialis |
|---|---|---|
| Mechanism | Central CNS (brain) | Peripheral (blood flow) |
| Works for Women | ✓ Yes | ✗ No |
| Requires Sexual Stimulation | Not required | Required |
| Cardiovascular Risk | Minimal | Yes (nitrate interaction) |
| Duration of Effect | 6–12 hours | 4–6 hours (Viagra) / up to 36h (Cialis) |
| Addresses Low Desire | ✓ Yes | No (only physical response) |
| Combinable with ED Meds | ✓ Yes | N/A |
| Common Side Effect | Mild nausea (dose-dependent) | Headache, flushing, vision changes |
PT-141 offers a uniquely comprehensive approach to sexual health — addressing desire, arousal, and response at the neurological level.
PT-141 is used on-demand — taken 1–2 hours before anticipated sexual activity. Your provider will determine the right dose and form for you.
| Form | Dose | Timing |
|---|---|---|
| Injection (SubQ) | 0.5–2 mg | 1–2 hours before activity |
| Nasal Spray | 1 spray per nostril | 1–2 hours before activity |
| Starting Dose (new users) | 0.5–1 mg | Titrate up to minimize nausea |
* Nausea is dose-dependent and most common at 2mg+. Starting at 0.5–1mg significantly reduces this side effect. PT-141 should not be used more than once in 24 hours. Protocol set by your licensed provider.
PT-141 is priced per vial with approximately 5 uses per 10mg vial at standard 2mg dosing. No subscription required — order as needed.